Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.
Also called NCT01375764
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 160 participants
- Sponsor
- Registry
-
NCT01375764
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Belgium, Canada, Denmark, Finland, Spain, Sweden
- Registry status
- Completed
Technical summary
Registry record NCT01375764. Randomized; quadruple masking; primary purpose treatment. Start 2011-07-28 (actual); primary completion 2012-05-08 (actual). Results posted on 2015-12-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects
- Acronym
- GAUSS
- Condition
- Hyperlipidemia
- Intervention (Biological)
- Evolocumab
- Intervention (Drug)
- Ezetimibe
- Intervention (Other)
- Placebo to Evolocumab
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct01375764- Content hash
4dd7936e4dd4ba090b331775546eaa2f852cae722ed741df6ab49e9acbd545f6